MH
Elegen is a cell-free DNA synthesis company that manufactures long, high-accuracy DNA using a proprietary microfluidics platform. Its ENFINIA product line delivers linear DNA (up to 7 kb in 6–8 business days) and plasmid DNA (up to 15 kb in 10 business days), NGS-verified at 99.999% per-base accuracy. Customers span agriculture, chemical, healthcare, and pharma sectors. The GEN II platform features the first directed-split-pool synthesizer with AI-driven cell-free DNA cloning for high-diversity synthesis.
Elegen is a cell-free DNA synthesis company that manufactures long, high-accuracy DNA using a proprietary microfluidics platform. Its ENFINIA product line delivers linear DNA (up to 7 kb in 6–8 business days) and plasmid DNA (up to 15 kb in 10 business days), NGS-verified at 99.999% per-base accuracy. Customers span agriculture, chemical, healthcare, and pharma sectors. The GEN II platform features the first directed-split-pool synthesizer with AI-driven cell-free DNA cloning for high-diversity synthesis.
Founded in 2017 by Matt Hill in San Carlos, California, Elegen was built on the premise that cell-based cloning creates fundamental bottlenecks in DNA synthesis — contamination, recombination, and slow turnaround. Hill and the founding team developed a cell-free microfluidics approach to produce longer, more accurate DNA faster. The company was backed by Andreessen Horowitz, 8VC, and KdT Ventures, and has since expanded to clinical manufacturing DNA for vaccine and medicine developers.
Elegen announced that it now ships plasmid DNA up to 15 kb in just 10 business days, delivering NGS-verified clonal plasmids globally with unprecedented speed for long DNA synthesis.
GenomeWeb reported on Elegen's $35M Series B financing round, noting its plans to expand into clinical-grade manufacturing and key strategic partnership with GSK.
GSK entered a collaboration and licensing agreement with Elegen to use its proprietary cell-free DNA manufacturing technology in developing GSK's vaccines and medicines. GSK also invested in Elegen's Series B as a strategic investor.
Elegen announced a $35 million Series B financing round led by Triatomic Capital with participation from GSK, a16z, KdT Ventures, 8VC, and others. The round supports expansion into clinical-grade DNA manufacturing for vaccines and medicines.
Elegen unveiled its GEN II platform featuring the world's first directed-split-pool synthesizer combined with a fully automated AI-driven cell-free DNA cloning system, enabling low-cost, high-diversity gene synthesis at scale.
GenomeWeb covered Elegen's growing customer base and fundraising momentum, highlighting the company's cell-free gene synthesis platform as a differentiated approach in the synthetic DNA market.
Elegen closed a Series A financing round (undisclosed amount) led by KdT Ventures, with participation from Andreessen Horowitz, 8VC, Digitalis Ventures, Alix Ventures, and ACVC Partners.
Matt Hill founded Elegen in San Carlos, California, in 2017 with the vision of using microfluidics and cell-free biology to produce longer, higher-accuracy DNA faster than traditional cell-based methods.
$35M raised total